r/pennystocks

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

FRMM IS THE PLAY FR SURE :- Short interest peaked at around 4.0 million shares during April and May and has since declined to approximately 3.4 million shares, indicating that a meaningful portion of shorts has already covered.
Despite that, short interest has remained remarkably resilient over the past two months while the stock has continued to trend higher. Yet, due to relatively light trading volume, the type of explosive move normally associated with a short squeeze has not occurred-at least not yet.
Key Trend Over the Last Two Weeks
Price: +16.7%
7 Green Days / 2 Red Days
Strongest Up Days
• +8.07% → 445,920 shares
• +7.30% → 419,825 shares
Largest Down Day
• -6.05% → 185,485 sharesFact-Based Analysis
Over the past two weeks, FRMM has consistently traded on higher volume during advances and lower volume during declines. Strong rallies were supported by heavy volume, while pullbacks occurred on significantly lighter volume. This type of volume profile is generally considered a bullish

Not financial advice. I'm long and biased. DYOR. Binary biotech bet. Phase 3 fails and you lose everything. All claims based on public SEC filings, ClinicalTrials.gov (NCT06072612), and exchange data.

Yo can someone tell me where I'm wrong here because either I'm an idiot or this is the craziest risk/reward I've stumbled into in a long time.

Setup in 30 seconds:

BriaCell ($$BCTX, ~$3, market cap ~$$27M) is running a pivotal Phase 3 in metastatic breast cancer. The trial is event-driven. It doesn't end on a calendar date. It ends when 144 patients die. That's when they crack it open and publish.

They guided topline data for H1-2026. We're in July now. Nothing yet.

...isn't that good?

The math that keeps me up at night:

Event-driven OS trial. Interim analysis fires at a fixed number of deaths. Deaths are coming slower than the statisticians modeled. Why?

1. Drug is working. Patients living longer. Fewer deaths. Delayed readout.

2. Control arm is also doing better than expected (better background care these days). Both arms live longer. Delayed, but no drug advantage.

3. Enrollment was slow so patients just haven't been in long enough yet.

Ok so which one is it?

Enrollment crossed 230 in May 2026. 160+ were already in by Dec 2025. So a big chunk has real follow-up time. (3) isn't fully dead as an explanation but it's weakening.

The DSMB cleared the study for the 6th time in a row, May 2026. No concerns. These guys would pull the plug if the drug clearly wasn't doing anything. They didn't. Catastrophic failure is basically off the table.

Phase 2 showed 16.6 months median OS (biomarker-selected group) vs 7-11 months for standard chemo. If even half that advantage holds in Phase 3, deaths should be coming in slower.

I can't prove it's (1). But delayed events + DSMB keeps greenlighting + Phase 2 showed doubled survival... ngl that points in one direction. Tell me where I'm wrong.

Now the part that makes my hands shake. The Immunomedics thing:

1. Company called Immunomedics. Phase 3 called ASCENT. Similar patient population: heavily pre-treated metastatic breast cancer, OS endpoint, head-to-head vs physician's choice chemo.

2. They hit. Five months later Gilead wrote a check for $21 billion. $88/share. All cash.

3. Now, Immunomedics already had FDA approval and actual revenue when they got bought. BriaCell doesn't. That's why it's sitting at $27M and not $2.7B. But that's also exactly why the asymmetry exists.

$27 million market cap. For a company with:

• FDA Fast Track
• Trial featured in Nature Medicine "Eleven clinical trials that will shape medicine in 2026"
• 70+ sites including Mayo Clinic, Penn/Abramson, Cedars-Sinai, Yale/Smilow, Emory Winship, Dartmouth
• CEO (Dr. Williams) who helped push Jakafi and Olumiant through at Incyte/GSK

If Phase 3 confirms Phase 2... this isn't a $27M company. It's not a $270M company. The Immunomedics comp, even if you discount it 90% for being pre-approval, still says billions. A lottery ticket with actual odds, idk.

Bear case, because I'm not a shill:

• Phase 3 misses and this thing goes to zero. Going concern is real. They burn cash.
• Dilution. Warrants everywhere (BCTXW/L/Z) + they'll raise capital the second the stock pops. Caps per-share upside
• "Delayed data = drug works" has holes. It's suggestive, not proof. I said it myself.
• 4.8% SI. This is NOT a squeeze play. Tiny float (~7.8M) and borrow is expensive (~20%) but don't come in here thinking this is GME. It's not. Buy it if you believe in the science or don't buy it at all.

tldr:

$27M cap. Phase 3 breast cancer. Doubled survival in Phase 2. Data delayed in event-driven trial (bullish if you understand the design). DSMB keeps saying continue. Last company that ran a similar play got bought for $21 billion.

Either I'm making a huge logical error or this is genuinely asymmetric. Someone poke holes. Seriously.

💎🙌

Position: Long BCTX. Not investment advice. Binary outcome. You can lose 100%.

I know most reverse splits end badly.
But there have to be some exceptions.
What’s the biggest comeback you’ve seen after a reverse split? 5x? 10x? More?
What actually changed? New management? New business? Just hype?
Trying to find a few examples and hear the stories behind them.

Helloww Guyzz..

After all, the amount of volume is everything when it comes to penny stocks. Volume is indeed everything with penny stocks, after all.

Hey again. I think we discussed charts and fundamentals recently and I'm aware that it can be still be trying to read the Matrix with all those numbers flashing at you all the time. If you currently have a chart in front of you and are thinking, "What is important?," I want to make that easier for you to understand.

Volume is the one thing that no one will tell you that you need in order to make it in this market. I’ve been trading since 2018 and can confidently say that I missed out on volume as the most costly trading mistake I made. So, let's take a breath, have a drink and chat about what volume actually is and how you can put it to use to keep yourself safe.

Let's see how this comes to the "real world".

Just the Crowd is The Restaurant Analogy.

Before even examining a stock chart, consider your travels down the street in a new city seeking a restaurant to eat at.

You visit a restaurant that has a large and attention-grabbing neon sign that says "Best Burgers in Town. It's priced right, its marketing is excellent. However, on looking through the window one sees that everything is empty. No one at all. No one whatsoever. Do you plan to consume the food there? Probably not. If the food was really great, you would know, because you'd have a crowd.

Volume on the stock market is the same. It's just that the total amount of shares that are being purchased and being sold within a certain time. It will inform you whether the restaurant is occupied, or if a line is out the door.

When trading penny stocks, the last thing you would want is to be the only one sitting in the restaurant.(I think I explained this clearly, if not please comment box is yours)

Lack of attention: Low Volume: The Trap

Let's put this into a real scenario of trading. Suppose that you are monitoring a penny stock that has a ticker symbol of $ECHO.

You get up, check and see that $ECHO has just rallied 20% for the day. The blood pumps a bit more rapidly. The fear of missing out is in effect, the price is flying. You're wanting to purchase now.

However, you can see the volume bars at the bottom of the chart. The volume for the whole morning is only 4,000 shares.

Penny stocks are very cheap to move; it doesn't take much money to move penny stocks. One trader can move a few thousand dollars worth of $ECHO alone causing the price to rise 20%. The problem is, if you do purchase those shares, then who are you going to be able to sell them to when you need to get your profit? There are no patrons at the restaurant. When it comes to selling, there are no buyers and price will soar down.

When a website does not have a lot of volume and high price is involved, it is a huge red flag. It's a trick and a fool proof trick at that, for novices anyway.

High Volume: Riding the Wave

Let's now turn to the other side. Suppose that there is another company, ticker symbol $SURF.

$SURF has been flat for the past three weeks. It hasn't broken $0.50 and it typically trades only about 50,000 shares a day. You're almost about to remove it from your list of watches.

But today in the first half hour of the market's opening, $SURF has been trading 15 million shares. The price pushes past $0.50, then $0.60, then $0.70.

The line out the door is one of these. The huge volume surge is a sign that thousands of other traders (and huge institutional money) are coming in. This is no normal one in his basement, it's a tidal wave. If it's that big, you know that you can get in and out of the trade safely, since there's a lot of liquidity available. If you wish to sell your shares in five minutes, then there are thousands of people that are waiting to purchase your shares from you.

Greeting cards for Christmas and New Year's are available. Christmas and New Year's cards are in stock.

You might want to follow all of the green percent signs you find, but in the stock market, volume will be your greatest lie detector.

The Golden rule of a volume - If there is no big volume with the price

breakout, it is not a price breakout. When it comes to price, that's the claim, but with volume that's the proof.

The next time you see some penny stock going crazy, make the effort to first see the bottom of the chart. Is it trading hundreds of thousands (or millions) of shares? But it's not an empty room?

If you're disciplined and able to sit on your hands while you wait for the right volume, you'll make it in this game. Go slow, watch the charts and do not go into a chart when there is no crowd.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

I’ve been looking at the recent updates for Rezolve. I'm trying to find the holes in this thing because on paper the market basically gives the company no credit. I understand the general skepticism around small cap AI stocks since most of the sector is just pure hype with nothing behind it but this business actually seems to be building a real case.

Here is what I am weighing up at the moment.

On the bullish side of things the $300 million buyback mandate is a major talking point. Shareholders have approved it though it still needs UK High Court approval which is expected around mid September. It is obviously not an immediate cash injection and we shouldn't assume the full amount will definately be spent. Even so for a company of this size partnering with BTIG for block trades is a big move that shows a lot of confidence from management.

The revenue guidance jum p is probably the more important part. Management is saying they will do around $360 million in revenue for FY26. What caught my eye is that their unaudited Q1 revenue came in at roughly $60 million which actualy beats the full year total for the whole of 2025. They also think they will hit an ARR exit rate of over $500 million for 2026. The sheer scale of this growth is pretty big if they execute properly.

Then you have the Mashreq and Visa integration which looks like actual real world utility rather than just a vague partnership. This is a live card-linked rewards programme integrated with standard Visa payment rails and Mashreq Bank in the UAE. It basically shows that the tech has moved beyond the pilot phase and into active payments.

The blockchain and data infrastructure angle with Subsquid will probably turn off some traditional investors. However their data layer has scaled from handling 240 terabytes to 1.4 petabytes of data per day. If commerce shifts toward automated AI agents doing real-time payments this level of data capacity will be nessecary.

To remain objective I have looked into what the bears are saying but a lot of it feels like standard short seller noise rather than huge flaws. People point to the high short interest but that looks more like a crowded outdated trade that could easily backfire on them given the current revenue momentum. There is also some chat about the legal drama surrounding the commerce acquisition but this sort of corporate fighting and poison-pill noise happens all the time with hostile bids and usually gets sorted once the money is on the table. The only real point of caution is that the Q1 numbers are still unaudited so the market is naturally waiting for the official audited filings before moving the stock up. It's a fair point but it feels like a timing issue rather than a broken business.

Personally I do not think this company should be written off as a typical microcap just using AI as a marketing buzzword. They are putting themselves right in the middle of automated commerce and payments. Between the High Court decision in September the current revenue speed and live rollouts the risk-to-reward ratio looks good despite the clear volatility.

Am I overestimating management's guidance or are others tracking this setup? Any thoughts from anyone looking at the financials would be appreciated

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Defence Holdings (£ALRT) has just officially secured a £226K annual contract with the UK MoD. This follows from an initial announcement last month from the government, and the project is now officially running.

This marks the first known contract and revenue generating project for DH, and to have that be with the government is a massive milestone. It validates them as a supplier of AI services to the government and defence industry.

Official government announcement / details

Now that they're officially part of national infrastructure, it opens up massive opportunity in the future, particularly for a company worth just £30M right now. Not to mention the incoming government's plans to ban Palantir from some public services potentially opening up further doors for them.

I have been looking more closely at the hydrogen market lately, and one small Canadian company stood out because it is not approaching hydrogen as a standalone clean-energy story.

Element One Hydrogen & Critical Minerals Corp. trades on the CSE as EONE, and the basic idea behind the company is to combine geologic hydrogen with critical mineral recovery and potentially carbon storage.

The geology is the interesting part.

Certain ultramafic and mafic rocks can react with water and naturally generate hydrogen. EONE is looking at both finding naturally occurring hydrogen underground and, where the geology supports it, stimulating hydrogen generation by introducing water into favorable rock systems.

Source: Element One Hydrogen & Critical Minerals corporate presentation

That is still an early and technically challenging field. Geologic hydrogen has not been proven at commercial scale across the industry, and NREL has described it as poorly understood. But that is also why the space is getting more attention. The potential prize is not simply "clean hydrogen." It is whether hydrogen can be produced at a cost low enough to compete with conventional fossil-based hydrogen and expensive green hydrogen.

The demand backdrop makes that worth paying attention to.

Global hydrogen demand surpassed 100 million tonnes in 2025, growing almost 3 year over year. Most of that demand already comes from real industrial uses such as refining, ammonia, methanol and chemicals.

The problem is that clean hydrogen barely participates in this market.

Low-emission hуdrogen demаnd grеw .20 in 2025, the existing hydrogen market is already big but low-emissions supply still is roughly 0.1 of it.

That makes geologic hydrogen interesting to me. Demand already exits, challange is finding cleaner sources of it wile keeping cost under control.

EONE becomes more appealing when the critical minerals side is added.

The company is targeting potential recovery of materials including nickel, cobalt, manganese, magnesium, iron oxide and silica from ultramafic rock systems. Its sponsored research agreement with Columbia University is focused on geologic hydrogen stimulation, co-recovery of critical metals and possible CO2 storage through mineral carbonation.

EONE committed US$1.67 million over two years to that research program. One important caveat is that Columbia retains ownership of inventions and research results, while EONE has the option to negotiate licenses to certain inventions or information. So this is a legitimate research relationship, but it should not be confused with EONE automatically owning everything developed through the program.

The company's Washington State strategy is also worth following.

Through its Twin Sisters Olivine MOU, EONE is evaluating access to high-grade olivine feedstock and a possible plant site. The proposed concept involves an initial capacity of around 50,000 tonnes of olivine per year, with a demonstration facility targeting roughly 150 tonnes per day.

The potential outputs are not limited to hydrogen. They include natural hydrogen, Class 1 nickel concentrate, magnesium hydroxide, iron oxide and silica.

That multi-output model is probably the most interesting part of the entire thesis.

A pure hydrogen project lives or dies on hydrogen economics. A traditional junior miner often depends on one deposit and one commodity cycle. EONE is exploring whether the same rock system could potentially produce hydrogen, recover strategic minerals and store CO2.

Magnesium is a good example of why that could matter. U.S. primary magnesium production stopped in 2022, and U.S. net import reliance for magnesium metal was estimated above 75 percent in 2025. If EONE's olivine pathway can eventually produce commercially viable magnesium products alongside hydrogen and other materials, the strategic relevance becomes much broader than clean energy alone.

The company also has an option and earn-in agreement with Stone to H2, whose technology is based on staged recovery of hydrogen and critical minerals from ultramafic rock using fluid injection and solution mining, with potential CO2 storage in the same geological setting.

But the demand side explains why this kind of experiment is happening now.

Low-emissions hydrogen project spending reached nearly $7 billion in 2025, almost dоuble the previous year, and could approach $10 billion in 2026. The U.S. hydrogen roadmap sees strategic demand opportunities reaching 10 million tonnes annually by 2030, 20 million by 2040 and 50 million by 2050. The EU is targeting 10 million tonnes of domestic renewable hydrogen production plus 10 million tonnes of imports by 2030.

The more aggressive long-term scenarios go much further, although I would treat them as scenarios rather than forecasts. IRENA's 1.5°C pathway sees hydrogen and derivatives reaching 154 million tonnes by 2030 and 614 million tonnes by 2050. The Hydrogen Council's net-zero trajectory sees more than 660 million tonnes by 2050.

Source: PwC compilation of major global hydrogen demand scenarios

I find interesting about EONE that the thesis does not require every one of those forecasts to come true.

There is already a 100 million tonne hydrogen market. Clean production barely penetrates it. The U.S. is heavily dependent on imported critical minerals such as magnesium. Governments are spending money on domestic supply chains. Industry is looking for lower-carbon inputs.

EONE is basically trying to find out whether one geological platform can address several of those problems at once.

That is not proven, and this is a junior company. But as an interesting find, it is one of the more unusual resource stories I have come across lately where upside case is based on finding a potentially better way to supply markets that already exist.

I’ve noticed that every time a company announces a reverse split, people immediately act like it’s over.
I get why. A lot of reverse splits happen because companies are struggling.
But is a reverse split itself actually the problem, or is it just a symptom?
There have to be some companies that used a reverse split, fixed their business, and ended up doing well afterward. I’m not talking about the usual dilution disasters—I’m talking about real turnaround stories.
Curious to hear what examples you guys remember. Which reverse split stocks actually proved everyone wrong?

CSE: NRED finally gave the kind of ugly dip I actually wanted.

Not the cute “down 3%” dip.

The real flush into demand where everyone suddenly remembers junior miners are spicy and the comment section starts acting like the chart committed a crime.

That is the kind of candle I was waiting for.

I did not want to chase higher after the move. I wanted the panic zone. Lower demand. A volume reaction. A spot where the risk is actually easier to define instead of buying into everyone’s excitement.

This is the part of the chart where normal people say “yikes” and I start opening the order ticket.

The reason I care is that the story did not disappear because of one ugly candle.

NovaRed still has Wilmac. It still has the MetalCore AI angle. It still has the copper-gold-platinum target concept from the latest data review. North Lamont still has the 1,125 ppm copper-in-soil anomaly. The company still has geophysics, target refinement and drilling as the next real tests, subject to permit timing.

Nothing about that is low risk.

This is still a junior explorer. No resource, no mine, no production. Ugly candles can get uglier. That is the game.

But I would rather buy a scary candle near demand than chase a pretty candle after everyone already got comfortable.

My read: the chart finally gave me the kind of uncomfortable entry I wanted. If the thesis is still intact, this is exactly where I prefer to start paying attention.

The semiconductor industry faces an increasingly difficult challenge.

AI chips, GPUs, and next-generation processors require ever smaller, thinner, and more efficient capacitors for power delivery. Traditional capacitor technologies are approaching their physical limits, creating demand for new solutions.

Smoltek is developing one of those potential solutions.

After more than 20 years of research and development, the company has developed CNF-MIM capacitors based on carbon nanofibers. According to the company, the technology aims to deliver significantly higher capacitance density in a much smaller footprint while also offering the potential for 30–40% lower manufacturing costs compared with current leading technologies.

The technology was originally developed at Chalmers MC2, one of Europe's leading nanotechnology cleanrooms, and is now transitioning from lab to fab together with industrial partners.

Current partners include:

• ITRI (Taiwan) – the semiconductor research institute that helped establish companies such as TSMC and UMC, now supporting Smoltek's industrialization.

• Yageo Group – one of the world's largest capacitor manufacturers, currently validating Smoltek's first commercial capacitor platform, Gen-One.

• Heraeus Precious Metals – collaborating with Smoltek on applications within hydrogen technology.

Rather than building expensive manufacturing facilities, Smoltek's strategy is to license its technology, with potential future revenue coming from upfront payments, milestone payments, and recurring royalties through Service License Agreements (SLAs) and Joint Development Agreements (JDAs).

Beyond semiconductors, the company is also developing technology for PEM electrolysis, where its nanotechnology has demonstrated the potential to reduce iridium consumption by more than 95%, addressing one of the major cost challenges in green hydrogen production.

With a market capitalization of less than SEK 600 million (approximately $60 million USD), the company remains an early-stage deep-tech investment.

Recent Financing

Smoltek recently completed an oversubscribed rights issue, with subscriptions reaching approximately 184% of the offering.

Including the oversubscription allocation, the company raised approximately SEK 82.1 million (before issue costs and loan offsets).

According to CEO Magnus Andersson, the proceeds will be used to accelerate commercialization and industrial scaling, with the objective of securing future SLAs and JDAs, while targeting positive cash flow from 2027.

Why I'm Following Smoltek

- 20+ years of R&D

- Proprietary carbon nanofiber technology

- Industrial partners including ITRI, Yageo, and Heraeus

- Commercial validation currently underway

- Recently completed an oversubscribed (184%) financing

- Asset-light licensing business model

- Exposure to both AI semiconductor infrastructure and hydrogen technology

- Started trading on the U.S. OTC market under ticker SMLTF

- Extensive IP portfolio with more than 90 patents and patent applications protecting the company's core technologies and manufacturing processes.

Risks

This remains a pre-revenue company. Commercial agreements are not guaranteed, commercialization could take longer than expected, and future financing may still be required if licensing agreements are delayed.

I'm sharing this because I find it to be an interesting deep-tech company that appears to be approaching a key commercialization phase.

Not financial advice. I'd be interested to hear what others think, especially anyone with experience in semiconductor packaging, passive components, or power delivery.